Zelira Therapeutics Limited

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 06:58:07 16/07/2024 BST			5-day change	1st Jan Change
1.05 ^AUD	+31.25%		+135.96%	+16.67%

04:13am	Zelira Therapeutics Jumps 25% After Securing Australian Patents for Autism Formulations	MT
07-11	Zelira Therapeutics Secures US FDA Guidance for Autism Spectrum Disorder Therapy Program; Shares Surge 24%	MT

Zelira Therapeutics Limited announced that it has received $1.4 million in funding

July 03, 2024

On July 4, 2024, Zelira Therapeutics Limited closed the transaction.

Latest news about Zelira Therapeutics Limited

Zelira Therapeutics Jumps 25% After Securing Australian Patents for Autism Formulations	03:13am	MT
Zelira Therapeutics Secures US FDA Guidance for Autism Spectrum Disorder Therapy Program; Shares Surge 24%	07-11	MT
Zelira Therapeutics Receives $1.4 Million Unsecured Loan from Chairman	07-04	MT
Zelira Therapeutics Limited announced that it has received $1.4 million in funding	07-03	CI
Zelira Therapeutics Obtains $1.4 Million Loan from Chairman	07-01	MT
Zelira Therapeutics Limited announced that it expects to receive $1.4 million in funding	06-30	CI
Zelira Therapeutics Receives Third-Tranche of Funding for HOPE Clinical Trials	05-23	MT
Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	04-15	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-22	CI
Zelira Therapeutics Secures Grant Funding for Cannabinoid Product	01-08	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	11-15
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/08/23	CI
Zelira Therapeutics Limited Announces Board Changes	31/05/23	CI
Transcript : Zelira Therapeutics Limited - Special Call	31/05/23
Zelira Therapeutics Bags Nearly AU$5 Million More Investment for HOPE SPV; Shares Rise 4%	22/05/23	MT
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding	21/05/23	CI
Zelira Therapeutics Raises AU$1.8 Million Via Placement	15/03/23	MT
Zelira Therapeutics Halts Securities Trading Pending Capital Raising Announcement	13/03/23	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Transcript : Zelira Therapeutics Limited - Special Call	22/02/23
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director	20/02/23	CI
Zelira Therapeutics Secures Nearly $9 Million Funding for US Clinical Trials of HOPE	15/02/23	MT
Zelira Therapeutics Secures R&D Tax Rebate	30/01/23	MT
Zelira Therapeutics Completes Drug Trial Patient Enrolment	21/11/22	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	16/11/22

Chart Zelira Therapeutics Limited

Duration

Period

More charts

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Sector

Biotechnology & Medical Research

Calendar

28/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZELIRA THERAPEUTICS LIMITED	+16.67%	6.15M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs